▲ +266.46% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for ObsEva in the last 3 months. The average price target is $11.80, with a high forecast of $28.00 and a low forecast of $4.00. The average price target represents a 266.46% upside from the last price of $3.22.
The current consensus among 5 investment analysts is to hold stock in ObsEva. This rating has held steady since December 2020, when it changed from a Buy consensus rating.
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.